ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Haoyu Shi
Matched on ORCID iD 0009-0000-0432-799X; OpenAlex author ID A5115605040. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2025: 2 papers · 2026: 2 papers
Papers 4
- Acinar-ductal metaplasia in pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-026-01251-0↗
- IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis. Co-author DOI 10.1016/j.gendis.2025.101866↗
- Lymphatic metastasis in pancreatic cancer: from bedside to bench and back. Co-author DOI 10.1007/s10555-025-10297-9↗
- Nuclear localization of YAP in pancreatic cancer: More players besides Hippo pathway. Co-author DOI 10.1016/j.canlet.2025.217864↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zeru Li · 4 shared papers, 2025–2026 · strength 1.07
- Paper Acinar-ductal metaplasia in pancreatitis and pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-026-01251-0↗
- Paper IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis. DOI 10.1016/j.gendis.2025.101866↗
- Paper Lymphatic metastasis in pancreatic cancer: from bedside to bench and back. DOI 10.1007/s10555-025-10297-9↗
- Yiping Xie · 3 shared papers, 2025–2026 · strength 0.81
- Paper Acinar-ductal metaplasia in pancreatitis and pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-026-01251-0↗
- Paper IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis. DOI 10.1016/j.gendis.2025.101866↗
- Paper Nuclear localization of YAP in pancreatic cancer: More players besides Hippo pathway. DOI 10.1016/j.canlet.2025.217864↗
- Bangbo Zhao · 3 shared papers, 2025–2026 · strength 0.78
- Paper IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis. DOI 10.1016/j.gendis.2025.101866↗
- Paper Lymphatic metastasis in pancreatic cancer: from bedside to bench and back. DOI 10.1007/s10555-025-10297-9↗
- Paper Nuclear localization of YAP in pancreatic cancer: More players besides Hippo pathway. DOI 10.1016/j.canlet.2025.217864↗
- Yutong Zhao · 3 shared papers, 2025–2026 · strength 0.78
- Paper IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis. DOI 10.1016/j.gendis.2025.101866↗
- Paper Lymphatic metastasis in pancreatic cancer: from bedside to bench and back. DOI 10.1007/s10555-025-10297-9↗
- Paper Nuclear localization of YAP in pancreatic cancer: More players besides Hippo pathway. DOI 10.1016/j.canlet.2025.217864↗
- Cheng Yong Qin · 3 shared papers, 2025–2026 · strength 0.78
- Paper IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis. DOI 10.1016/j.gendis.2025.101866↗
- Paper Lymphatic metastasis in pancreatic cancer: from bedside to bench and back. DOI 10.1007/s10555-025-10297-9↗
- Paper Nuclear localization of YAP in pancreatic cancer: More players besides Hippo pathway. DOI 10.1016/j.canlet.2025.217864↗
- Weibin Wang · 3 shared papers, 2025–2026 · strength 0.78
- Paper IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis. DOI 10.1016/j.gendis.2025.101866↗
- Paper Lymphatic metastasis in pancreatic cancer: from bedside to bench and back. DOI 10.1007/s10555-025-10297-9↗
- Paper Nuclear localization of YAP in pancreatic cancer: More players besides Hippo pathway. DOI 10.1016/j.canlet.2025.217864↗
- Tianyu Li · 2 shared papers, 2025–2026 · strength 0.52
- Cheng Qin · 1 shared paper, 2026 · strength 0.29
- Yutong Zhao · 1 shared paper, 2026 · strength 0.29
- Xiangyu Zhang · 1 shared paper, 2026 · strength 0.29
- Weibin Wang · 1 shared paper, 2026 · strength 0.29
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.